Updated:
RedHill Biopharma Ltd.
RedHill Biopharma Ltd.: Founded 2009, Tel Aviv-based specialty pharma focused on GI and infectious disease therapies, led by Dror Ben-Asher.
RedHill Biopharma Ltd.
RedHill Biopharma Ltd. was founded in 2009 by Dror Ben-Asher, Ori Shilo, and others. The firm emerged as a specialty pharmaceutical company targeting gastrointestinal diseases and infectious diseases, with a commercial-stage pipeline that includes both approved and development-stage therapies. The company's strategy centers on in-licensing and developing late-stage drug candidates with known mechanisms of action, reducing regulatory risk. RedHill's marketed portfolio includes Movelat (for musculoskeletal pain) and Talicia (for Helicobacter pylori infection); its pipeline includes opaganib and RHB-107, which were evaluated in COVID-19 trials. Geographically, operations span Israel and the US via its Raleigh, NC base. The firm has partnerships with companies like SRL Pharma (per public filings, 2023). RedHill trades on the Nasdaq (RDHL) and Tel Aviv Stock Exchange. Team size is not publicly disclosed, but the firm maintains a lean structure typical of specialty pharma. In April 2023, the company received a US patent for opaganib in gastroenterology indications. The firm's most distinctive structural characteristic is its hybrid operating company model: it is a commercial-stage biopharma, not a venture capital firm, generating revenue from product sales rather than management fees. This aligns incentives directly with drug commercialization milestones.
General information
Firm type
Asset Manager
Year founded
2009
AUM
Undisclosed
Location
Region
Middle East
Country
Israel
City
Tel Aviv
Corporate office
Tel Aviv, Israel
Additional offices
Raleigh, NC, United States
Principals
Dror Ben-Asher
Executive Chairman
Guy Goldberg
Chief Executive Officer
Rick Scruggs
Chief Financial Officer
Sector focus
Frequently asked questions
What is RedHill Biopharma's business model?
RedHill is a specialty pharmaceutical company that develops and commercializes late-stage drug candidates for gastrointestinal and infectious diseases. It generates revenue from product sales (e.g., Talicia for H. pylori) and uses that income to fund ongoing R&D. This self-sustaining model is unusual among developmental biotechs.
Who founded RedHill Biopharma?
RedHill was founded in 2009 by Dror Ben-Asher and Ori Shilo. Ben-Asher serves as Executive Chairman and is the company's longest-serving leader.
What are RedHill's key therapeutic areas?
The company focuses on gastrointestinal diseases (e.g., H. pylori infection, gastroparesis) and infectious diseases. Its marketed drugs include Talicia (H. pylori) and Movelat (musculoskeletal pain). Pipeline candidates include opaganib for COVID-19 and other conditions.
Does RedHill have commercial-stage revenue?
Yes. RedHill has two FDA-approved products — Talicia and Movelat — which generate revenue. This distinguishes it from many development-stage biotechs that lack commercial income.
Is RedHill publicly traded?
Yes. RedHill Biopharma is listed on Nasdaq under the ticker RDHL and also trades on the Tel Aviv Stock Exchange. This provides public market visibility and access to capital.
What is RedHill's geographic presence?
The company is headquartered in Tel Aviv, Israel, with operational offices in Raleigh, North Carolina. It markets products in the US and has partnerships in other regions.
How has RedHill funded its R&D?
RedHill funds its R&D primarily through product sales and public equity offerings, rather than venture capital or private equity. This non-dilutive revenue model supports ongoing clinical trials without external investment.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: